The 2026 Fierce Pharma Marketing Awards did something more interesting than name this year’s standout campaigns. They changed what counts as award-worthy pharma marketing.
For the first time, the awards included dedicated categories for Data-Driven Campaign and Point of Care Marketing. Among 20 categories, those additions may look like small changes. However, they offer a useful signal about where pharma marketing is heading. The industry is increasingly recognizing work based not only on what audiences see, but also on how intelligently marketers use data and where engagement happens in the healthcare journey.
Table of Contents
- Why new award categories matter
- Data-driven marketing moves into the spotlight
- Point of care becomes a strategic channel
- What these changes mean for pharma brand teams
- Conclusion
- FAQs
How Pharma Marketing Trends Are Changing What Gets Rewarded
Awards programs do more than celebrate good creative work. They also reflect what an industry believes deserves attention.
For years, familiar categories such as television, social media, public relations, websites, and professional marketing provided a recognizable picture of pharmaceutical promotion. Those areas still matter. Yet adding Data-Driven Campaign and Point of Care Marketing suggests that the picture is expanding.
The 2026 Fierce Pharma Marketing Awards formally recognized both disciplines as standalone categories. The Data-Driven Campaign award went to Tarsus Pharmaceuticals and Moon Rabbit for “Xdemvy: Finding the Invisible Patient.” The campaign used a predictive framework designed to identify patients who had not yet been diagnosed with demodex blepharitis.
Meanwhile, UCB, OLIXIR New York, and Spectrum Science won the Point of Care Marketing category for the “Fintepla Video Book.” The physical and digital resource was designed to educate caregivers of children with rare diseases, including Dravet syndrome and Lennox-Gastaut syndrome.
Neither campaign abandons creativity. Instead, each connects creative execution with a more specific moment, audience, or measurable need.
That distinction matters because it reflects a broader shift in pharmaceutical marketing. Increasingly, marketers are being asked not simply whether a campaign attracted attention, but whether it reached the right audience at a meaningful time.
Data-Driven Pharma Marketing Moves Beyond the Dashboard
Data has been part of pharmaceutical marketing for years. What appears to be changing is its role.
Instead of functioning mainly as a reporting layer after a campaign runs, data can increasingly shape who gets reached, when they get reached, and what marketers learn next. That makes data part of campaign strategy rather than simply campaign measurement.
This shift also creates new challenges. As Pharma Marketing Network recently explored, marketers can now receive different performance answers from DSPs, publishers, clean rooms, agencies, and outcomes datasets. Those systems may each measure different populations, exposure definitions, or time periods.
Consequently, having more data does not automatically produce better decisions.
The emerging opportunity is to connect meaningful signals with action. Predictive models, first-party engagement information, claims data, EHR information, prescription data, and other real-world datasets can provide different views of the patient and HCP journey.
For example, de-identified laboratory data is also gaining attention because it may provide more timely clinical signals than some traditional datasets. Fierce Pharma has highlighted its potential for helping commercial teams identify physicians and patient populations at relevant stages of the treatment journey.
Therefore, one of the most important changes in pharma marketing may be the shift from collecting data to actually putting it to work.
The award category makes that transition visible. Data is no longer simply sitting behind the campaign. Increasingly, it can help determine how the campaign works.
Point-of-Care Marketing Gets Closer to the Decision
The arrival of a dedicated point-of-care award may be even more revealing.
Traditional pharmaceutical advertising often tries to influence a future healthcare decision. A consumer sees an advertisement at home, searches online, and perhaps remembers the message during a later appointment.
Point-of-care marketing changes that distance.
It places relevant information closer to moments when patients, caregivers, pharmacists, and healthcare professionals are actively thinking about care. Those environments can include waiting rooms, exam rooms, EHR platforms, patient portals, pharmacies, and telehealth experiences.
Industry investment reflects that growing importance. According to the Point of Care Marketing Association, point-of-care marketing surpassed $1 billion in revenue in 2024. Meanwhile, the definition of the channel continues to broaden as digital tools become more closely integrated with clinical workflows.
That expansion helps explain why point-of-care marketing is becoming a bigger part of pharma strategy.
However, proximity to healthcare decisions also raises the bar for relevance. A message delivered during a healthcare interaction has to fit the context. Otherwise, better targeting simply creates a more precisely delivered interruption.
That means successful point-of-care strategy may depend on understanding what a patient or HCP needs in that moment. Education, affordability information, adherence support, clinical resources, and conversation tools can all play different roles.
In other words, point of care is becoming less about placement and more about usefulness.
What These Changes Mean for Pharma Brand Teams
The new awards do not mean traditional creative channels are disappearing. In fact, the same Fierce awards recognized television, social media, influencer campaigns, websites, podcasts, PR, and other forms of marketing.
Instead, the additions suggest that the definition of strong marketing is becoming broader.
Creative quality still matters. Yet data quality, audience precision, context, timing, and measurable outcomes are increasingly part of the same conversation.
That creates an interesting challenge for agencies and brand teams. A memorable campaign may still generate attention, but marketers increasingly need to understand what happens after that attention. Did the campaign reach an appropriate audience? Did it support a useful healthcare conversation? Can teams connect exposure to meaningful actions? Most importantly, can those conclusions be supported by reliable measurement?
The growing importance of these questions is also visible in pharma marketing data and measurement, where HCP engagement, patient behavior, omnichannel analytics, and ROI increasingly shape campaign planning.
AI adds another layer. As patients and healthcare professionals use chatbots and answer engines to find health information, marketers are also considering how brands appear within AI-generated answers. Some industry strategists now describe this as moving beyond traditional “share of voice” toward understanding a brand’s presence within answers generated by AI systems.
Taken together, these developments point toward a more connected model. Creative, data, technology, distribution, and measurement are becoming harder to separate.
Conclusion
Award categories are not market forecasts. Still, they can reveal what an industry has decided is important enough to recognize.
The addition of Data-Driven Campaign and Point of Care Marketing to the 2026 Fierce Pharma Marketing Awards offers one such signal. Data is moving closer to campaign strategy, while marketing itself is moving closer to healthcare decision-making.
For pharmaceutical marketers, that may be the bigger story behind the trophies.
The next generation of successful campaigns may still need a compelling idea. However, changes across pharmaceutical marketing suggest that marketers will increasingly be judged on what surrounds that idea: the data behind it, the context in which it appears, the audience it reaches, and the actions that follow.
The question is no longer simply, “Did people see it?”
Increasingly, it is, “Did it matter when they did?”
FAQs
What are the biggest pharma marketing trends in 2026?
Key developments include greater use of data-driven targeting and measurement, point-of-care engagement, AI-assisted marketing, integrated HCP and patient strategies, and stronger attention to measurable healthcare actions.
Why is point-of-care marketing becoming more important?
Point-of-care marketing can reach patients and healthcare professionals when they are actively thinking about healthcare decisions. Digital clinical platforms, telehealth, patient portals, and other technologies have also expanded where these interactions can occur.
What is data-driven pharmaceutical marketing?
Data-driven pharmaceutical marketing uses relevant datasets and analytics to improve audience identification, campaign planning, personalization, optimization, and measurement. The goal is to turn reliable signals into better marketing decisions.
Are traditional pharma advertising channels becoming less important?
Not necessarily. Television, social media, websites, PR, events, and other channels remain significant. However, marketers increasingly need to connect those channels with data, audience context, and measurable outcomes.
Why do the new Fierce Pharma Marketing Award categories matter?
Awards do not determine the direction of the industry. However, creating dedicated Data-Driven Campaign and Point of Care Marketing categories indicates that these disciplines have become established enough to receive standalone recognition alongside traditional marketing categories.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
